Y Intercept Hong Kong Ltd Lowers Position in Oric Pharmaceuticals, Inc. $ORIC

Y Intercept Hong Kong Ltd cut its stake in shares of Oric Pharmaceuticals, Inc. (NASDAQ:ORIC) by 67.2% during the 1st quarter, Holdings Channel.com reports. The fund owned 111,992 shares of the company’s stock after selling 229,431 shares during the period. Y Intercept Hong Kong Ltd’s holdings in Oric Pharmaceuticals were worth $1,419,000 as of its most recent SEC filing.

A number of other hedge funds have also recently bought and sold shares of the company. Federation des caisses Desjardins du Quebec grew its stake in shares of Oric Pharmaceuticals by 100.0% in the 4th quarter. Federation des caisses Desjardins du Quebec now owns 4,000 shares of the company’s stock worth $33,000 after acquiring an additional 2,000 shares in the last quarter. Caitong International Asset Management Co. Ltd lifted its position in shares of Oric Pharmaceuticals by 184.4% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 4,528 shares of the company’s stock valued at $37,000 after purchasing an additional 2,936 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its position in shares of Oric Pharmaceuticals by 26.0% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,732 shares of the company’s stock valued at $39,000 after purchasing an additional 977 shares in the last quarter. Russell Investments Group Ltd. bought a new position in shares of Oric Pharmaceuticals during the third quarter valued at about $60,000. Finally, CANADA LIFE ASSURANCE Co purchased a new position in Oric Pharmaceuticals during the third quarter worth about $65,000. 95.05% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on ORIC shares. Citigroup reduced their price objective on shares of Oric Pharmaceuticals from $17.00 to $16.00 and set a “buy” rating for the company in a research report on Tuesday, May 5th. Weiss Ratings restated a “sell (d-)” rating on shares of Oric Pharmaceuticals in a research note on Tuesday, April 21st. Wall Street Zen lowered Oric Pharmaceuticals from a “hold” rating to a “strong sell” rating in a report on Saturday, May 9th. Wedbush decreased their price target on Oric Pharmaceuticals from $20.00 to $17.00 and set an “outperform” rating for the company in a research report on Wednesday, April 1st. Finally, Stifel Nicolaus assumed coverage on Oric Pharmaceuticals in a research report on Friday, June 12th. They issued a “buy” rating and a $14.00 price objective on the stock. Thirteen equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $19.27.

Oric Pharmaceuticals Stock Performance

ORIC traded down $0.09 during midday trading on Friday, reaching $10.85. The company had a trading volume of 1,058,241 shares, compared to its average volume of 1,649,456. Oric Pharmaceuticals, Inc. has a 12-month low of $7.23 and a 12-month high of $14.93. The business has a 50-day moving average price of $9.00 and a two-hundred day moving average price of $10.11. The stock has a market cap of $1.12 billion, a PE ratio of -7.53 and a beta of 1.02.

Oric Pharmaceuticals (NASDAQ:ORIC) last issued its quarterly earnings results on Monday, May 4th. The company reported ($0.34) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.31) by ($0.03). On average, research analysts anticipate that Oric Pharmaceuticals, Inc. will post -1.45 earnings per share for the current year.

About Oric Pharmaceuticals

Oric Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company headquartered in South San Francisco, California. The firm is dedicated to discovering and developing small molecule therapeutics designed to overcome resistance mechanisms in solid tumor oncology. Its research efforts focus on identifying novel targets and advancing precision medicines that can restore or enhance patient response when standard therapies fail.

The company’s pipeline features lead candidates such as ORIC-101, a selective, orally available antagonist of the glucocorticoid receptor currently being evaluated in Phase 1/2 trials for patients with solid tumors who have acquired resistance to chemotherapy and hormonal agents.